TY - JOUR
T1 - Effects of growth hormone-releasing hormone on sleep and brain interstitial fluid amyloid-β in an APP transgenic mouse model
AU - Liao, Fan
AU - Zhang, Tony J.
AU - Mahan, Thomas E.
AU - Jiang, Hong
AU - Holtzman, David M.
N1 - Funding Information:
Dr. Holtzman’s lab at Washington University received research grants from the NIH, Cure Alzheimer’s Fund, the Tau Consortium, Eli Lilly, AstraZeneca, Janssen, and C2N Diagnostics. He is on the scientific advisory board of C2N Diagnostics and has consulted in the last year for Genentech, Eli Lilly, and AstraZeneca.
Funding Information:
We obtained m266 and 3D6B antibodies as a gift from Eli Lilly and Company. This work was supported by the Ellison Medical Foundation (DMH) and NIH P01NS074969 (DMH).
Publisher Copyright:
© 2014 Elsevier Inc..
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Alzheimer's disease (AD) is a neurodegenerative disorder characterized by impairment of cognitive function, extracellular amyloid plaques, intracellular neurofibrillary tangles, and synaptic and neuronal loss. There is substantial evidence that the aggregation of amyloid β (Aβ) in the brain plays a key role in the pathogenesis of AD and that Aβ aggregation is a concentration dependent process. Recently, it was found that Aβ levels in the brain interstitial fluid (ISF) are regulated by the sleep-wake cycle in both humans and mice; ISF Aβ is higher during wakefulness and lower during sleep. Intracerebroventricular infusion of orexin increased wakefulness and ISF Aβ levels, and chronic sleep deprivation significantly increased Aβ plaque formation in amyloid precursor protein transgenic (APP) mice. Growth hormone-releasing hormone (GHRH) is a well-documented sleep regulatory substance which promotes non-rapid eye movement sleep. GHRHR. lit/lit mice that lack functional GHRH receptor have shorter sleep duration and longer wakefulness during light periods. The current study was undertaken to determine whether manipulating sleep by interfering with GHRH signaling affects brain ISF Aβ levels in APPswe/PS1δE9 (PS1APP) transgenic mice that overexpress mutant forms of APP and PSEN1 that cause autosomal dominant AD. We found that intraperitoneal injection of GHRH at dark onset increased sleep and decreased ISF Aβ and that delivery of a GHRH antagonist via reverse-microdialysis suppressed sleep and increased ISF Aβ. The diurnal fluctuation of ISF Aβ in PS1APP/GHRHR. lit/lit mice was significantly smaller than that in PS1APP/GHRHR. lit/+ mice. However despite decreased sleep in GHRHR deficient mice, this was not associated with an increase in Aβ accumulation later in life. One of several possibilities for the finding is the fact that GHRHR deficient mice have GHRH-dependent but sleep-independent factors which protect against Aβ deposition.
AB - Alzheimer's disease (AD) is a neurodegenerative disorder characterized by impairment of cognitive function, extracellular amyloid plaques, intracellular neurofibrillary tangles, and synaptic and neuronal loss. There is substantial evidence that the aggregation of amyloid β (Aβ) in the brain plays a key role in the pathogenesis of AD and that Aβ aggregation is a concentration dependent process. Recently, it was found that Aβ levels in the brain interstitial fluid (ISF) are regulated by the sleep-wake cycle in both humans and mice; ISF Aβ is higher during wakefulness and lower during sleep. Intracerebroventricular infusion of orexin increased wakefulness and ISF Aβ levels, and chronic sleep deprivation significantly increased Aβ plaque formation in amyloid precursor protein transgenic (APP) mice. Growth hormone-releasing hormone (GHRH) is a well-documented sleep regulatory substance which promotes non-rapid eye movement sleep. GHRHR. lit/lit mice that lack functional GHRH receptor have shorter sleep duration and longer wakefulness during light periods. The current study was undertaken to determine whether manipulating sleep by interfering with GHRH signaling affects brain ISF Aβ levels in APPswe/PS1δE9 (PS1APP) transgenic mice that overexpress mutant forms of APP and PSEN1 that cause autosomal dominant AD. We found that intraperitoneal injection of GHRH at dark onset increased sleep and decreased ISF Aβ and that delivery of a GHRH antagonist via reverse-microdialysis suppressed sleep and increased ISF Aβ. The diurnal fluctuation of ISF Aβ in PS1APP/GHRHR. lit/lit mice was significantly smaller than that in PS1APP/GHRHR. lit/+ mice. However despite decreased sleep in GHRHR deficient mice, this was not associated with an increase in Aβ accumulation later in life. One of several possibilities for the finding is the fact that GHRHR deficient mice have GHRH-dependent but sleep-independent factors which protect against Aβ deposition.
KW - Alzheimer's disease
KW - Amyloid-β
KW - Growth hormone-releasing hormone
KW - Sleep
UR - http://www.scopus.com/inward/record.url?scp=84930752673&partnerID=8YFLogxK
U2 - 10.1016/j.bbi.2014.09.005
DO - 10.1016/j.bbi.2014.09.005
M3 - Article
C2 - 25218899
AN - SCOPUS:84930752673
SN - 0889-1591
VL - 47
SP - 163
EP - 171
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
ER -